Webpage Traffic View All

Job Posts View All

Business Outlook View All

C4 Therapeutics - AI Stock Analysis

Analysis generated July 6, 2025

C4 Therapeutics is a biopharmaceutical company focused on pioneering targeted protein degradation science to address diseases caused by protein dysregulation. Located in Watertown, Massachusetts, C4 Therapeutics is focused on developing a robust portfolio of small molecule therapies designed to degrade disease-causing proteins. The company employs an innovative and promising approach to treatment development, leveraging a diversified pipeline to tackle a variety of unmet medical needs.

Fundamental Analysis

Revenue for the last quarter was $7.2 million. This represents a significant increase of 39.81% compared to the previous quarter, indicating positive growth momentum. When compared to the same quarter last year, the revenue growth is substantial at 138.17%, suggesting robust year-over-year expansion.

Net income for the last quarter stood at $26 million, reflecting an increase of 23.87% from the previous quarter. This positive growth further translates to a 7.19% increase compared to the same quarter last year, marking solid financial performance.

The EBITDA for the last quarter was recorded at $0. While this might initially seem concerning, it's actually a positive indicator in this context, as it's a 100.00% increase from both the previous quarter and the same quarter last year. This suggests significant progress in streamlining operations and improving financial health.

Technical Analysis

Today's stock price is $1.50. This represents a decrease of 13.29% compared to a month ago, which may be concerning for short-term investors. Over the longer term, the stock price has decreased by 66.81% compared to a year ago, indicating potential long-term challenges.

The current trend is bearish. The current 10-day simple moving average (SMA10) is $1.47, which is the same as the previous SMA10, suggesting a potential consolidation or continued downward trend in the near term. The Relative Strength Index (RSI) is at 67.2, indicating a neutral condition and no immediate overbought or oversold signals.

Alternative Data Analysis

Considering job postings and employee sentiment, C4 Therapeutics currently has 0 open positions according to data from the most popular job boards. This number has decreased by 100% in the last couple of months, possibly implying cost-cutting measures or improved efficiency, although not a great sign for a company looking to grow.

On a positive note, 82% of C4 Therapeutics employees have a positive business outlook, which is encouraging for company morale and productivity. However, web traffic metrics show a decrease in customer acquisition with an estimated 5,000 visitors to their webpage, down by 29% in the last couple of months, indicating potential challenges in customer engagement and retention.

Meanwhile, C4 Therapeutics' customer engagement on social platforms like Twitter stands at 1,800 followers, with no significant change recently. The AltIndex AI score for the company stands at 66, which is a buy signal based on a combination of fundamental, technical, and alternative data analyses.

Conclusion and Recommendation

In summary, C4 Therapeutics demonstrates remarkable fundamental growth, with significant year-over-year increases in revenue and net income. However, the technical indicators reveal a bearish trend, and the substantial decrease in stock price over the past year could be concerning to potential investors.

The alternative data provides a mixed picture, with positive employee sentiment contrasted by worrisome trends in job openings and customer acquisition. Despite these concerns, the positive AltIndex AI score suggests a favorable outlook based on a holistic analysis of available data signals.

Given the combination of solid fundamental performance, bearish technical indicators, and mixed alternative data signals, investors may consider cautiously optimistic strategies. Monitoring the company’s next few quarters to capture any continuous growth or further developments could be prudent before making an investment decision.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.